Sarnoff wins GMDC achievment award
COLORADO SPRINGS, Colo. Norton Sarnoff, president of Handi-Foil, won the Global Market Development Center’s 2008 Lifetime Achievement Award at the General Merchandise Marketing Conference Sunday in Orlando, Fla.
Sarnoff has worked in business for more than 50 years, mostly in aluminum foil products. He sold EZ POR, a company he inherited from his father, in 1979 and founded Handi-Foil in 1984. Based in Wheeling, Ill., Handi-Foil today has 700 employees and 650,000 square feet of manufacturing and distribution space.
Sarnoff was a member of GMDC’s general merchandise advisory board from 1985 to 1992, serving as the organization’s president in 1991. He has attended every General Merchandise Marketing Conference for the last 38 years.
GMDC is a trade association of General Merchandise and Health Beauty Wellness retailers, wholesalers and suppliers.
CHPA’s Suydam receives FDA alumni award
WASHINGTON Food and Drug Administration Commissioner Andrew von Eschenbach on Thursday afternoon recognized Linda Suydam, president of the Consumer Healthcare Products Association, as an honored recipient of FDA’s Distinguished Alumni Award, the association announced.
The citation for Suydam’s achievement reads: “For exceptional management of FDA programs in medical devices, radiological health and agency-wide, and leadership to fight abuse and ensure safe use of over-the-counter medicines.”
“On behalf of CHPA’s board of directors, we are pleased that Linda has been recognized for her dedication and continued commitment toward improving public health, and remain grateful to have the benefit of her extensive experience with FDA on behalf of the consumers who rely on over-the-counter medicines and nutritional supplements, “ stated CHPA chairman John Hendrickson, executive vice president of global operations and supply chain at Perrigo.
Prior to joining CHPA as its president in 2002, Suydam enjoyed a 21-year career at FDA, rising from an entry-level position to senior associate commissioner, the highest-ranking, non-political executive position at FDA.
Since joining CHPA , Suydam has directed the establishment of the CHPA Educational Foundation whose goal is improved public health through safe and effective OTC use; increased opportunities for synergistic cooperation between member firms by establishing the annual Market Exchange and retail immersion events; and enhanced the association’s positive relationship with the FDA through educational seminars, conferences, and joint learning opportunities.
FDA calls for recall of supplement marketed for ED
ROCKVILLE, Md. The Food and Drug Administration today requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person’s blood pressure and can cause other life-threatening side effects.
These lots of Xiadafil VIP Tabs bear an expiration date of September 2009 and are marketed as a dietary supplement for sexual enhancement and able to treat erectile dysfunction.
Today’s formal request follows an action by the state of Florida to prevent the further distribution of this product into consumer channels. FDA is advising consumers not to buy or use this product. The agency may take further regulatory action to protect consumers from this illegal product.
Although labeled as a dietary supplement and touted as “all-natural,” Xiadafil VIP Tabs are an illegally marketed drug that contains a potentially harmful undeclared ingredient, the FDA stated. FDA chemical analysis revealed that Xiadafil VIP Tabs contains hydroxyhomosildenafil, which is an analog of sildenafil, the active ingredient in Viagra, an FDA-approved prescription drug for ED.
“Because these products are labeled as ‘all natural dietary supplements,’ consumers may assume that they are harmless and pose no health risk,” stated Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “But an unsuspecting consumer with underlying medical issues may take these products without knowing that they can cause serious side effects and interact in dangerous ways with drugs that a consumer is already taking.”
On May 13 Florida officials issued a “stop sale” action at SEI’s distribution facility in Miami, Fla. This action required the firm to hold, intact, violative Xiadafil VIP Tabs found on-hand at the facility. The state of Florida’s action to control the supply of the product, coupled with today’s formal request by FDA to recall this product from the marketplace, will further reduce the likelihood that this potentially dangerous product is used by unsuspecting consumers.